The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer

Journal of Pathology

Volumn 204, Issue 2, 2004, Pages 159-166

  Comuzzi, Barbara ^a   Nemes, Constanze ^b   Schmidt, Stefan ^c   Jasarevic, Zerina ^b   Lodde, Michele ^d   Pycha, Armin ^d   Bartsch, Georg ^a   Offner, Felix ^b   Culig, Zoran ^a   Hobisch, Alfred ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b General Hospital Feldkirch   (Austria)

^c TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^d CENTRAL HOSPITAL OF BOLZANO   (Italy)

Author keywords

Androgen; Androgen receptor; CBP; Co activators; Endocrine therapy; Interleukin 6; Prostate cancer; Prostate cancer cell line

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYPROTERONE ACETATE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR; GONADORELIN; HYDROXYFLUTAMIDE; INTERLEUKIN 6; JANUS KINASE; MESSENGER RNA; METRIBOLONE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PEPTIDE HORMONE; SOMATOMEDIN C; STEROID;

ADVANCED CANCER; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; CELL LINE, TUMOR; CREB-BINDING PROTEIN; DOWN-REGULATION; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MALE; METRIBOLONE; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER; RNA, NEOPLASM; TRANS-ACTIVATORS; TYRPHOSTINS; UP-REGULATION;

EID: 5044232836     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1609     Document Type: Article

References (42)

1. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61: 3550-3555.
2. Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994; 54: 1566-1573.
3. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61: 2892-2898.
4. Culig Z, Klocker H, Bartsch G, Hobisch A. Androgen receptors in prostate cancer. Endocr Rel Cancer 2002; 9: 155-170.
5. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med 1999; 5: 280-285.
6. Hobisch A, Ramoner R, Fuchs D, et al. Prostate cancer cells (LNCaP) generated after long-term interleukin-6 treatment express interleukin-6 and acquire an interleukin-6-partially resistant phenotype. Clin Cancer Res 2001; 7: 2941-2948.
7. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003; 9: 370-376.
8. Zhang L, Johnson M, Le KH, et al. Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res 2003; 63: 4552-4560.
9. Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L, Slingerland J. Involvement of p27 (Kip1) in G1 arrest by high dose 5alpha-dihydrotestosterone in LNCaP human prostate cancer cells. Oncogene 2000; 19: 670-679.
10. Sadar MD, Gleave ME. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res 2000; 60: 5825-5831.
11. Hobisch A, Eder I, Putz T, et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998; 58: 4640-4645.
12. Livengood JA, Scoggin KE, van Orden K, et al. p53 transcriptional activity is mediated through the SRC1-interacting domain of CBP/p300. J Biol Chem 2002; 277: 9054-9061.
13. Fronsdal K, Engedal N, Slagsvold T, Saatcioglu F. CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem 1998; 273: 31 853-31 859.
14. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315-4319.
15. Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN. Expression of RAC3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 2001; 85: 1928-1936.
16. Halkidou K, Gnanapragasam VJ, Mehta PB, et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003; 22: 2466-2477.
17. Li P, Yu X, Ge K, Melamed J, Roeder RG, Wang Z. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 2002; 161: 1467-1474.
18. Comuzzi B, Lambrinidis L, Rogatsch H, et al. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol 2003; 162: 233-241.
19. Debes JD, Schmidt LJ, Huang H, Tindall DJ. p300 mediates interleukin-6-dependent transactivation of the androgen receptor. Cancer Res 2002; 62: 5632-5636.
20. Debes JD, Sebo TJ, Lohse CM, Murhpy LM, Haugen de AL, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003; 63: 7638-7640.
21. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001; 159: 159-165.
22. Peterziel H, Culig Z, Stober J, et al. Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Int J Cancer 1995; 63: 544-550.
23. Tan J, Sharief Y, Hamil KG, et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997; 11: 450-459.
24. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332: 1393-1398.
25. Joyce R, Fenton MA, Rode P, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159: 149-153.
26. Haapala K, Hyytinen ER, Roiha M, et al. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab Invest 2001; 81: 1647-1651.
27. Hara T, Miyazaki J, Araki H, et al. Novel mutations of androgen receptor - a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63: 149-153.
28. Culig Z, Hoffmann J, Erdel M, et al. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999; 81: 242-251.
29. Gao, M, Ossowski L, Ferrari AC. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J Cell Physiol 1999; 179: 336-346.
30. Veldscholte J, Voorhost-Ogink MM, Bolt-de Vries J, van Rooij HC, Trapman J, Mulder E. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochim Biophys Acta 1990; 1052: 187-194.
31. Misiti S, Schomburg L, Yen PM, Chin WW. Expression and hormonal regulation of coactivator and corepressor genes. Endocrinology 1998; 139: 2493-2500.
32. Thenot S, Charpin M, Bonnet S, Cavailles V. Estrogen receptor cofactors expression in breast and endometrial human cancer cells. Mol Cell Endocrinol 1999; 156: 85-93.
33. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 2000; 42: 88-98.
34. Campbell CL, Jiang Z, Savarese DM, Savarese TM. Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am J Pathol 2001; 158: 25-32.
35. Chung TD, Yu JJ, Kong TA, Spiotto MT, Lin JM. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate 2000; 42: 1-7.
36. MacDonald A, Habib FK. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br J Cancer 1992; 65: 177-182.
37. Jones HE, Eaton CL, Barrow D, Dutkowski CM, Gee JM, Griffiths K. Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor-alpha and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines. Prostate 1997; 30: 219-231.
38. Iwamura M, Sluss PM, Casamento JB, Cockett AT. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 1993; 22: 243-252.
39. Nishimura K, Ting HJ, Harada Y, et al. Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Res 2003; 63: 4888-4894.
40. Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S, Sonoo H. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, and corepressors in breast cancer. Clin Cancer Res 2000; 6: 512-518.
41. Dhir R, Ni Z, Lou W, de Miguel F, Grandis JR, Gao AC. Stat3 activation in prostatic carcinomas. Prostate 2002; 51: 241-246.
42. Steiner H, Godoy-Tundidor S, Rogatsch H, et al. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 2003; 162: 655-663.